User:Mr. Ibrahem/Piflufolastat F-18

Piflufolastat F-18, sold under the brand name Pylarify, is a radioactive diagnostic agent used in positron emission tomography (PET) imaging. Specifically it is used to image prostate cancer that is prostate-specific membrane antigen (PSMA) positive to look for spread or recurrence. It is given by injection into a vein.

Common side effects include headache, altered taste, and tiredness. Other side effects may include allergic reactions and radiation exposure.

Piflufolastat F-18 was approved for medical use in the United States in 2021. It is not approved in either Europe or the United Kingdom as of 2022.